Therapeutic advances in hormone-dependent cancers: Focus on prostate, breast and ovarian cancers

Michael Ulm, Arvind V. Ramesh, Keely M. McNamara, Suriyan Ponnusamy, Hironobu Sasano, Ramesh Narayanan

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)


Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.

Original languageEnglish
Pages (from-to)R10-R26
JournalEndocrine Connections
Issue number2
Publication statusPublished - 2019


  • Breast cancer
  • Drug development
  • Ovarian cancer
  • Prostate cancer
  • Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Therapeutic advances in hormone-dependent cancers: Focus on prostate, breast and ovarian cancers'. Together they form a unique fingerprint.

Cite this